Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484861 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4815560 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL8483813 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4812770 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL11050599 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4951882 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4954181 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL890725 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL483847 | 0.94 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4193998 | 0.93 | RECQL (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1393394-B1 | CONDUCTIVE POLYAMINE-BASED ELECTROLYTE | UNIV OKLAHOMA (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1095031-B1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2013-08-21 | — | — | EP | disclosed |
| US-7709486-B2 | antiviral compounds 1,4,8,11-tetraazacyclotetradecane derivatives for against HIV-infected cells, to inhibit the binding by the natural ligand to its chemokine receptor; viricides | GENZYME CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7569079-B2 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2009-08-04 | — | — | US | disclosed |
| US-20080287454-A1 | CXCR4 ANTAGONISTS | BRIDGER GARY J | 2008-11-20 | — | — | US | disclosed |
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2008-10-30 | — | — | US | disclosed |
| US-7414065-B2 | Methods to modulate conditions mediated by the CXCR4 receptor | GENZYME CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-7390595-B2 | Method of preparing a crosslinked polymer in an electrolyte composition | FUJIFILM CORPORATION (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20050154005-A1 | Methods to modulate conditions mediated by the CXCR4 receptor | GENZYME CORPORATION | 2005-07-14 | — | — | US | disclosed |
| US-6872714-B1 | Methods to modulate conditions mediated by the CXCR4 receptor | ANORMED INC. (CA) | 2005-03-29 | — | — | US | disclosed |
| US-5886007-A | USEFUL TO TREAT ALZHEIMER'S DISEASE WITH REDUCED SIDE EFFECT | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1999-03-23 | — | — | US | disclosed |
| US-5783584-A | USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-07-21 | — | — | US | disclosed |
| WO-1997021681-A1 | THA ANALOGS USEFUL AS CHOLINESTERASE INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | KRT18, CKMT1A; CKMT1B, XRCC5 | ALDH1A1 2546/4885CYP3A4 1652/4885CYP2C9 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.